[Myo-inositol in the treatment of polycystic ovary syndrome].

OBJECTIVE: Presentation of a comprehensive body of knowledge on the role of insulin sensitizer myo-inositol in the treatment of polycystic ovary syndrome (PCOS).

DESIGN: Review article.

SETTING: Institute for the Care of Mother and Child, Prague.

METHOD: An overview of publishing data.

RESULTS AND CONCLUSION: Polycystic ovary syndrome is the most common cause of ovarian dysfunction and anovulatory infertility in women. The insulin resistance occurs very frequently as a part of PCOS. This paper reviews the literature documenting the effectiveness of insulin sensitizer myo-inositol in the treatment of ovarian dysfunction, symptoms of hyperandrogenism and wide complex of symptoms of metabolic syndrome. Six randomized controlled trials provides evidence of a positive effect of myo-inositol to normalize ovarian function, improve laboratory and clinical manifestations of hyperandrogenism and insulin resistance. The myo-inositol treatment has been demonstrated as a safe method of PCOS management.